Yes, non-GLP-1 appetite suppressants or metabolic agents may supplement GLP-1 therapy in some patients, but they tend to be less effective when used alone and have different risk profiles
Given the relatively recent approval of semaglutide 2.4 mg and tirzepatide, real-world evidence on the effectiveness of these therapies for chronic weight management is limited
Identifying Your Risk: Genetic Factors and Personalized Assessment Not everyone who takes semaglutide experiences OCD symptoms, which suggests that individual genetic and neurobiological factors play a critical role
The gentle wall-flow method dissolves the powder without agitation
Particular vigilance is advised with medications that have a narrow therapeutic index (such as warfarin, where INR monitoring may be prudent) or those requiring rapid absorption
The study included a large sample size and a long follow-up time and used multiple databases to investigate a diverse population